VERAXA Biotech AG shareholders approved the merger with Veraxa Biotech Holding AG and the issuance of new shares to Voyager Acquisition Corp. at an Extraordinary General Meeting on February 27, 2026. This approval is a prerequisite for the closing of the proposed business combination between VERAXA, Veraxa Biotech Holding AG, and Voyager Acquisition Corp. (NASDAQ: VACH). The merger will involve Veraxa Biotech Holding AG acquiring VERAXA and subsequently changing its name to Veraxa Biotech AG. VERAXA will continue to operate under its existing management team, led by Chief Executive Officer, Christoph Antz. An ordinary capital increase of a maximum of CHF 223,400.00 was approved, with corresponding shares offered to Voyager shareholders. The combined company is expected to trade on NASDAQ under the symbol VRXA, subject to Voyager's shareholder approval.